Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 7, 2004, Pages 1206-1214

  Slattery, Martha L ^a,d   Samowitz, Wade ^a   Curtin, Karen ^a   Ma, Khe Ni ^a   Hoffman, Michael ^a   Caan, Bette ^b   Neuhausen, Susan ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IGF1 GENE; IGFBP3 GENE; IRS1 GENE; IRS2 GENE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; ALLELES; CALIFORNIA; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RISK FACTORS; UTAH;

EID: 3142770705     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
2. Singh P, Rubin N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 1993;105:1218-37.
3. Rui L, Fisher TL, Thomas J, White MF. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J Biol Chem 2001;276:40362-7.
4. Werner H, Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997;8:71-92.
5. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37.
6. Burks D, White M. IRS proteins and β-cell function. Diabetes 2001;50:S140-5.
7. White MF. Insulin signaling in health and disease. Science 2003;302:1710-1.
8. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF. Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signaling. Nat Genet 1999;23:32-40.
9. Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency irfipairs brain growth and promotes phosphorylation. J Neurosci 2003;23:7084-92.
10. Withers DJ. Insulin receptor substrate proteins and neuroendocrine function. Biochem Soc Trans 2001;29:525-9.
11. Van Obberghen E, Baron V, Scimeca JC, Kaliman P. Insulin receptor: receptor activation and signal transduction. Adv Second Messenger Phosphoprotein Res 1993;28:195-201.
12. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
13. Ma J, Giovannucci E, Pollak M, et al. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst 2001;93:1330-6.
14. McCarty MF. Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. Med Hypotheses 1997;48:297-308.
15. Giovannucci E, Pollak M, Liu Y, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers & Prev 2003;12:84-9.
16. Probst-Hensch NM, Wang H, Goh VHH, Seow A, Lee H-P, Yu MC. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Cancer Epidemiol Biomarkers & Prev 2003;12:739-46.
17. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109S-20S.
18. Rosen CJ, Glowacki J, Craig W. Sex steroids, the insulin-like growth factor regulatory system, and aging: implications for the management of older postmenopausal women. J Nutr Health Aging 1998;2:39-44.
19. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, Accili D. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and β-cell compensation to insulin resistance. J Biol Chem 2002;277:36740-7.
20. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-80.
21. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers & Prev 2001;10:377-84.
22. Zou T, Fleisher AS, Kong D, et al. Sequence alterations of insulin-like growth factor binding protein 3 in neoplastic and normal gastrointestinal tissues. Cancer Res 1998;58:4802-4.
23. Chokkalingam AP, McGlynn KA, Gao Y-T, et al. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res 2001;61:4333-6.
24. Cussenot O, Valeri A. Heterogeneity in genetic susceptibility to prostate cancer. 2001;12:11-6.
25. DeLellis K, Ingles S, Kolonel L, et al. IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 2003;88:277-82.
26. Jernstrom H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001;72:144-54.
27. Federici M, Petrone A, Porzio O, et al. The Gly972→Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes 2003;52:887-90.
28. Lautier C, El Mkadem SA, Renard E, et al. Complex haplotypes of IRS2 gene are associated with severe obesity and reveal heterogeneity in the effect of Gly1057Asp mutation. Hum Genet 2003;113:34-43.
29. Rosen CJ, Kurland ES, Vereault D, et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
30. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
31. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer-beyond physical activity. Cancer Res 1997;57:75-80.
32. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin- dependent diabetes mellitus. Lancet 1993;342:828-32.
33. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:4297-300.
34. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002;63:317-32.
35. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-80.
36. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992;3:452-6.
37. Stumvoll M, Fritsche A, Volk A, et al. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans. Diabetes 2001;50:882-5.
38. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001;15:2099-111.
39. Federici M, Hribal ML, Ranalli M, et al. The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J 2001;15:22-4.
40. Sir-Petermann T, Perez-Bravo F, Angel B, Maliqueo M, Calvillan M, Palomino A. G972R polymorphism of IRS-1 in women with polycystic ovary syndrome. Diabetologia 2001;44:1200-1.
41. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. J Clin Invest 1996;97:2569-75.
42. Baroni MG, Arca M, Sentinelli F, et al. The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance. Diabetologia 2001;44:367-72.
43. Kovacs P, Hanson RL, Lee Y-H, et al. The role of insulin receptor substrate-1 gene (IRS1) in type 2 diabetes in Pima Indians. Diabetes 2003;52:3005-9.
44. Rojas FA, Hirata AE, Saad MJ. Regulation of insulin receptor substrate-2 tyrosine phosphorylation in animal models of insulin resistance. Endocrine 2003;21:115-22.
45. Hennige AM, et al. Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes. J Clin Invest 2003;112:1521-32.
46. Lee AV, et al. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39-47.
47. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 1993;7:743-52.
48. Ma J, et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 2000;10:S28-9.
49. Manousos O, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-7.
50. Zenilman ME, Graham W. Insulin-like growth factor I receptor messenger RNA in the colon is unchanged during neoplasia. Cancer Invest 1997;15:1-7.
51. Adenis A, et al. Type I insulin-like growth factor receptors in human colorectal cancer. Eur J Cancer 1995;31A:50-5.
52. Oh Y. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine 1997;7:111-3.
53. Michell NP, et al. Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors 1997;14:269-77.
54. Guo YS, et al. Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology 1992;102:1101-8.
55. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
56. Russo A, et al. Body size and colorectal-cancer risk. Int J Cancer 1998;78:161-5.
57. Slattery ML, Benson J, Murtaugh M. An evaluation of energy intake, energy expenditure, and BMI: energy balance and rectal cancer. Nutr Cancer 2003;46:166-71.
58. Franceschi S, et al. Dietary glycemic load and colorectal cancer risk. Ann Oncol 2001;12:173-8.
59. Slattery ML, et al. Dietary sugar and colon cancer. Cancer Epidemiol Biomarkers & Prev 1997;6:677-85.
60. Schernhammer ES, et al. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003;107:60-4.